ISSN: 2577-4379
Authors: Wu Y and Chen GY*
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has caused the coronavirus disease 2019 (COVID-19) pandemic, resulting in millions of infections and deaths worldwide. Although vaccines are available, they appear to be less efficacious against newly emerging variants of the virus. Thus, therapeutic modalities are urgently needed. The coronavirus genome encodes four major structural proteins: the spike (S) protein, nucleocapsid (N) protein, membrane (M) protein, and envelope (E) protein, all of which are required to produce a structurally complete viral particle. N protein is one of the most abundant structural proteins, participates in the regulation of viral replication and virion assembly, and is a major immunogen in coronavirus infection-induced disease. Sialylation is the addition of sialic acids to the terminal glycans of glycoproteins and glycolipids, which act as key components for biological functions of glycoproteins or glycolipids. Sialidases (or neuraminidases) are glycosidases that remove sialic acid residues (desialylation) from glycan portions of glycoproteins or glycolipids. Through desialylation, sialidases modulate the functionality of sialic acid-containing molecules and are involved in both physiological and pathological pathways. This review aims to explore the current understanding of NEU1's involvement in coronavirus infection and pathogenesis, synthesizing available research and identifying areas for future investigation.
Keywords: SARS-CoV-2; COVID-19; Sialylation, Sialidases
